130 related articles for article (PubMed ID: 34806575)
1. [A case of pyoderma gangrenosum associated to bevacizumab, angiogenesis role in its etiology].
Maray-Mateos I; Álvarez-Asteinza C; Carbajales-Álvarez M; Lozano-Blázquez A
Farm Hosp; 2021 Sep; 45(6):340-341. PubMed ID: 34806575
[No Abstract] [Full Text] [Related]
2. Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report.
Kim HS; Kwon JE; Park YJ
Acta Derm Venereol; 2023 Aug; 103():adv9646. PubMed ID: 37526292
[No Abstract] [Full Text] [Related]
3. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia.
Montoto S; Bosch F; Estrach T; Blade J; Nomdedeu B; Nontserrat E
Leuk Lymphoma; 1998 Jun; 30(1-2):199-202. PubMed ID: 9669691
[TBL] [Abstract][Full Text] [Related]
4. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy.
Lewerin C; Mobacken H; Nilsson-Ehle H; Swolin B
Leuk Lymphoma; 1997 Aug; 26(5-6):629-32. PubMed ID: 9389372
[TBL] [Abstract][Full Text] [Related]
5. A case of cabozantinib-induced pyoderma gangrenosum-like ulceration.
Matsudate Y; Ninomiya I; Sadamoto Y
Australas J Dermatol; 2023 Feb; 64(1):154-155. PubMed ID: 36305613
[No Abstract] [Full Text] [Related]
6. Pyoderma gangrenosum-like lesions provocated by botulinum injections.
Owczarczyk-Saczonek A; Zdanowska N; Wańczyk-Dręczewska B; Wygonowska E; Placek W; Griffiths CC; Griffiths TW
Dermatol Ther; 2020 Mar; 33(2):e13227. PubMed ID: 31957116
[TBL] [Abstract][Full Text] [Related]
7. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Dasanu CA; Bockorny B; Alexandrescu DT
J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
[TBL] [Abstract][Full Text] [Related]
8. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.
Benzaquen M; Monnier J; Beaussault Y; Rouby F; Berbis P
Australas J Dermatol; 2017 Nov; 58(4):e270-e271. PubMed ID: 28660635
[No Abstract] [Full Text] [Related]
9. Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis.
Aggarwal P
Dermatol Ther; 2020 Mar; 33(2):e13221. PubMed ID: 31925868
[TBL] [Abstract][Full Text] [Related]
10. ANCA positive propylthiouracil induced pyoderma gangrenosum.
Gungor K; Gonen S; Kisakol G; Dikbas O; Kaya A
J Endocrinol Invest; 2006 Jun; 29(6):575-6. PubMed ID: 16840840
[No Abstract] [Full Text] [Related]
11. Pyoderma gangrenosum of the scalp following hair highlights in a postpartum patient.
Gorpelioglu C; Sarifakioglu E
Eur J Dermatol; 2008; 18(1):97-8. PubMed ID: 18086612
[No Abstract] [Full Text] [Related]
12. Onset of pyoderma gangrenosum after tocilizumab therapy for Takayasu arteritis: A new undescribed paradoxical reaction.
Borgia F; Sutera D; Spagnolo A; Mazza F; Bertino L; Cannavò SP; Gallizzi R
Br J Clin Pharmacol; 2021 Aug; 87(8):3378-3379. PubMed ID: 33567476
[No Abstract] [Full Text] [Related]
13. Pyoderma gangrenosum possibly triggered by adalimumab.
Kikuchi N; Hiraiwa T; Ohashi T; Hanami Y; Satoh M; Takenoshita H; Yamamoto T
Eur J Dermatol; 2012; 22(6):804-5. PubMed ID: 23107608
[No Abstract] [Full Text] [Related]
14. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
[No Abstract] [Full Text] [Related]
15. Ibrutinib-induced pyoderma gangrenosum.
Sławińska M; Barańska-Rybak W; Sobjanek M; Wilkowska A; Mital A; Nowicki R
Pol Arch Med Wewn; 2016 Sep; 126(9):710-711. PubMed ID: 27698335
[No Abstract] [Full Text] [Related]
16. First case of lenvatinib-induced pyoderma gangrenosum: Possible management with dose reduction.
Miyagawa A; Adachi T; Takamiyagi S; Arakawa H; Matsushita M; Inazumi T
J Dermatol; 2021 May; 48(5):e221-e222. PubMed ID: 33651422
[No Abstract] [Full Text] [Related]
17. Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine.
Graziano F; Macaluso FS; Cassata N; Citrano M; Orlando A
Inflamm Bowel Dis; 2021 Aug; 27(9):e110-e111. PubMed ID: 34003258
[No Abstract] [Full Text] [Related]
18. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin.
Sinagra E; Orlando A; Renna S; Maida M; Cottone M
Inflamm Bowel Dis; 2012 Aug; 18(8):E1594-5. PubMed ID: 22038892
[No Abstract] [Full Text] [Related]
19. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab.
Jin K; Matsuzaki Y; Akasaka E; Nakano H; Sawamura D
J Dermatol; 2019 Mar; 46(3):e108-e109. PubMed ID: 30192400
[No Abstract] [Full Text] [Related]
20. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
Shenefelt PD
Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
